Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12–15 years: end-of-study results from a community-randomized study up to 6.5 years

Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12–15 years: end-of-study results from a community-randomized study up to 6.5 years

This manuscript discloses end-of-study safety data of a community-randomized controlled trial in Finland (NCT00534638), assessing the effectiveness of two vaccination strategies (gender-neutral versus females only) using the AS04-adjuvanted human papillomavirus (HPV)-16/18 (AS04-HPV-16/18) vaccine....

Full description

Bibliographic Details
Main Authors: Dan Bi, Dan Apter, Tiina Eriksson, Mari Hokkanen, Julia Zima, Silvia Damaso, Maaria Soila, Gary Dubin, Matti Lehtinen, Frank Struyf
Format: Article
Language:English
Published: Taylor & Francis Group 2020-06-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
human papillomavirus (hpv)
as04-adjuvanted hpv-16/18 vaccine
adolescents
safety
autoimmune disease
insulin-dependent diabetes mellitus
Online Access:http://dx.doi.org/10.1080/21645515.2019.1692557

Internet

http://dx.doi.org/10.1080/21645515.2019.1692557

Similar Items